>
SQZ Biotechnologies Co logo

SQZ - SQZ Biotechnologies Co Share Price

$11.88 0.6  4.9%

Last Trade - 9:10pm

Sector
Healthcare
Size
Small Cap
Market Cap £224.6m
Enterprise Value £103.4m
Revenue £14.9m
Position in Universe 4063rd / 6851
Bullish
Bearish
Unlock SQZ Revenue
Momentum
Relative Strength (%)
1m -11.8%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -69.0%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 12.7 20.1 21.0 22.0 29.7 +28.7%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, SQZBiotechnologies Co revenues increased 4% to $21M. Net lossincreased 57% to $50.5M. Revenues reflect Collaborationrevenue increase of 9% to $21M. Higher net loss reflectsResearch and development increase of 42% to $50.3M(expense), Interest income decrease of 73% to $550K(income), General and administrative increase of 8% to$18.2M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

SQZ Revenue Unlock SQZ Revenue

Net Income

SQZ Net Income Unlock SQZ Revenue

Normalised EPS

SQZ Normalised EPS Unlock SQZ Revenue

PE Ratio Range

SQZ PE Ratio Range Unlock SQZ Revenue

Dividend Yield Range

SQZ Dividend Yield Range Unlock SQZ Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
SQZ EPS Forecasts Unlock SQZ Revenue
Profile Summary

SQZ Biotechnologies Company is a clinical-stage biotechnology company. The Company is developing transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. It uses its technology, Cell Squeeze, to physically squeeze cells through a microfluidic chip, temporarily opening the cell membrane and enabling biologic material of interest, or cargo, to diffuse into the cell. Its SQZ Antigen Presenting Cells (SQZ APC) platform is in a Phase I trial in highly immunogenic (HPV) plus tumors. It is also developing SQZ Activating Antigen Carriers (SQZ AAC) and SQZ Tolerizing Antigen Carriers (SQZ TAC). Its SQZ APC platform is focused on generating robust (cluster of differentiation 8 (CD8) plus T cell responses. Its lead product candidate, SQZ- peripheral blood mononuclear cells (PBMC)-HPV, from its SQZ APC platform, is a targeted cancer vaccine that has been designed to generate antigen-specific CD8 plus T cell responses to attack HPV plus tumors.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
No. of Shareholders: 174
No. of Employees: 98
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange New York Stock Exchange
Shares in Issue 27,881,722
Free Float (0.0%)
Eligible for
ISAs
SIPPs
SQZ Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for SQZ
Upcoming Events for SQZ
Tuesday 15th June, 2021
SQZ Biotechnologies Co Annual Shareholders Meeting
Frequently Asked Questions for SQZ Biotechnologies Co
What is the SQZ Biotechnologies Co share price?

As of 9:10pm, shares in SQZ Biotechnologies Co are trading at $11.88, giving the company a market capitalisation of £224.6m. This share price information is delayed by 15 minutes.

How has the SQZ Biotechnologies Co share price performed this year?

Shares in SQZ Biotechnologies Co are currently trading at $11.88 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the SQZ Biotechnologies Co price has moved by % over the past year.

What are the analyst and broker recommendations for SQZ Biotechnologies Co?

There are no analysts currently covering SQZ Biotechnologies Co.

When will SQZ Biotechnologies Co next release its financial results?

SQZ Biotechnologies Co is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the SQZ Biotechnologies Co dividend yield?

SQZ Biotechnologies Co does not currently pay a dividend.

Does SQZ Biotechnologies Co pay a dividend?

SQZ Biotechnologies Co does not currently pay a dividend.

When does SQZ Biotechnologies Co next pay dividends?

SQZ Biotechnologies Co does not currently pay a dividend.

How do I buy SQZ Biotechnologies Co shares?

To buy shares in SQZ Biotechnologies Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of SQZ Biotechnologies Co?

Shares in SQZ Biotechnologies Co are currently trading at $11.88, giving the company a market capitalisation of £224.6m.

Where are SQZ Biotechnologies Co shares listed? Where are SQZ Biotechnologies Co shares listed?

Here are the trading details for SQZ Biotechnologies Co:

Country of listing: United States
Exchange: NYQ
Ticker Symbol: SQZ
What kind of share is SQZ Biotechnologies Co?

Based on an overall assessment of its quality, value and momentum, SQZ Biotechnologies Co is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a SQZ Biotechnologies Co share price forecast 2021?

Shares in SQZ Biotechnologies Co are currently priced at $11.88. At that level they are trading at 0.222% discount to the analyst consensus target price of 0.00.

Analysts covering SQZ Biotechnologies Co currently have a consensus Earnings Per Share (EPS) forecast of -2.525 for the next financial year.

How can I tell whether the SQZ Biotechnologies Co share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like SQZ Biotechnologies Co. Over the past six months, the relative strength of its shares against the market has been -57.9%. At the current price of $11.88, shares in SQZ Biotechnologies Co are trading at -44.11% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the SQZ Biotechnologies Co PE Ratio?

We were not able to find PE ratio data for SQZ Biotechnologies Co.

Who are the key directors of SQZ Biotechnologies Co?

SQZ Biotechnologies Co's management team is headed by:

Armon Sharei - CEO
Howard Bernstein - CSO
Amy Schulman - CHM
Klavs Jensen - CFD
Teri Loxam - CFO
Who are the major shareholders of SQZ Biotechnologies Co?

Here are the top five shareholders of SQZ Biotechnologies Co based on the size of their shareholding:

Polaris Capital Management, LLC Investment Advisor
Percentage owned: 10.77% (3.00m shares)
SunAmerica Asset Management, LLC Investment Advisor
Percentage owned: 9.04% (2.52m shares)
Temasek Holdings Pte. Ltd. Sovereign Wealth Fund
Percentage owned: 9.02% (2.51m shares)
AIG Asset Management (U.S.), LLC Investment Advisor
Percentage owned: 8.05% (2.25m shares)
Invus Public Equities Advisors, LLC Investment Advisor
Percentage owned: 5.76% (1.61m shares)
Similar to SQZ
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.